Compare JZXN & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZXN | PMCB |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 8.3M |
| IPO Year | 2020 | 2001 |
| Metric | JZXN | PMCB |
|---|---|---|
| Price | $0.88 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 272.6K | 166.7K |
| Earning Date | 02-24-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 277.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.63 |
| 52 Week High | $8.50 | $1.51 |
| Indicator | JZXN | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 46.54 |
| Support Level | $0.82 | $0.65 |
| Resistance Level | $1.15 | $0.80 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 16.51 | 28.57 |
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It is into trade business with a focus on sales of new energy batteries including design, commissioned processing, transportation and packaging, sales of electrical equipment, mobile phone accessories and other products. Its revenues consist of two reportable operating segments: (i) Sales of new energy batteries, including production, transportation, and packaging, in the mainland Pearl River Delta region; and(ii) Sales and production of electric vehicles in Southeast Asia, including two-wheelers, three-wheeled electric scooters, and slow-speed vehicles.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.